Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria.
CSU
DLQI
H1-anti-histamine
HADS
Hospital Anxiety and Depression Scale
UAS7
anxiety
chronic spontaneous urticaria
depression
omalizumab
psychiatric disorders
Journal
Future science OA
ISSN: 2056-5623
Titre abrégé: Future Sci OA
Pays: England
ID NLM: 101665030
Informations de publication
Date de publication:
10 Aug 2020
10 Aug 2020
Historique:
entrez:
25
11
2020
pubmed:
26
11
2020
medline:
26
11
2020
Statut:
epublish
Résumé
Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients before and after treatment with omalizumab. A total of 30 patients were enrolled in the study: 15 patients affected by CSU and treated with omalizumab and the other 15 healthy subjects did not receive any systemic therapy. All patients were evaluated using Hospital Anxiety and Depression Scale, CRP and erythrocyte sedimentation rate, at baseline and after 6 months. The omalizumab group after 6 months of therapy had a decrease of all the scores and biomarkers. Omalizumab allowed an improvement of urticaria and mental comorbidities.
Sections du résumé
BACKGROUND
BACKGROUND
Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients before and after treatment with omalizumab.
MATERIALS & METHODS
METHODS
A total of 30 patients were enrolled in the study: 15 patients affected by CSU and treated with omalizumab and the other 15 healthy subjects did not receive any systemic therapy. All patients were evaluated using Hospital Anxiety and Depression Scale, CRP and erythrocyte sedimentation rate, at baseline and after 6 months.
RESULTS
RESULTS
The omalizumab group after 6 months of therapy had a decrease of all the scores and biomarkers.
CONCLUSION
CONCLUSIONS
Omalizumab allowed an improvement of urticaria and mental comorbidities.
Identifiants
pubmed: 33235810
doi: 10.2144/fsoa-2020-0087
pmc: PMC7668119
doi:
Types de publication
Journal Article
Langues
eng
Pagination
FSO618Informations de copyright
© 2020 Laura Diluvio.
Déclaration de conflit d'intérêts
Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
Références
Psychosom Med. 2005 Sep-Oct;67(5):679-87
pubmed: 16204423
Br J Dermatol. 1999 Apr;140(4):667-71
pubmed: 10233318
J Dermatol. 2018 Aug;45(8):963-970
pubmed: 29897137
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
Curr Opin Allergy Clin Immunol. 2019 Aug;19(4):387-392
pubmed: 31246664
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
J Asthma Allergy. 2019 Sep 20;12:285-295
pubmed: 31571935
Caspian J Intern Med. 2018 Summer;9(3):228-231
pubmed: 30197766
Allergy. 2012 Dec;67(12):1465-74
pubmed: 22978406
Allergy. 2014 Jul;69(7):868-87
pubmed: 24785199
J Dermatol Sci. 1994 Oct;8(2):129-35
pubmed: 7841156
Transl Psychiatry. 2013 Apr 23;3:e249
pubmed: 23612048
Allergy Asthma Proc. 2014 Jan-Feb;35(1):4-9
pubmed: 24433591
J Eur Acad Dermatol Venereol. 2008 Jan;22(1):36-40
pubmed: 18181971
Eur Ann Allergy Clin Immunol. 2006 May;38(5):149-52
pubmed: 17058846
Psychosom Med. 2004 Sep-Oct;66(5):679-83
pubmed: 15385691
Arch Dermatol Res. 2013 Mar;305(2):99-104
pubmed: 23161175
Br J Dermatol. 2016 May;174(5):996-1004
pubmed: 26872037
Arch Dermatol Res. 2019 Dec;311(10):825-831
pubmed: 31520274
J Health Psychol. 2011 Oct;16(7):1038-47
pubmed: 21459916
Acta Derm Venereol. 2011 Sep;91(5):557-61
pubmed: 21597672
Allergy. 2011 Mar;66(3):317-30
pubmed: 21083565
Allergy. 2012 Oct;67(10):1289-98
pubmed: 22913638